CBP 105: ICI BREAST CANCER PRECEPTORSHIP
Multidisciplinary management, standards of care, optimal diagnostics, therapies, and future perspectives in the care of Breast Cancer patients in sub-Saharan Africa incorporating Biosimilars.
Training Dates: 27th June 2022- 4th August 2022
Training Duration: 6 weeks
Course Director: Prof. Fredrick Chite Asirwa MD
Consultant Physician. Medical Oncologist & Hematologist
Executive Director/CEO: International Cancer Institute (ICI)
P.O. Box 8088, Code 30100 Eldoret, Kenya
Lead Course Faculty:
Dr. Kevin Makori MD, MMED
Clinical & Radiation Oncologist
Deputy Director of Programs
International Cancer Institute (ICI)
P.O. Box 8088, Code 30100 Eldoret, Kenya
This educational activity is provided independently by International Cancer Institute (ICI)
through the Blueprint Program
Accreditation of this course is by KMPDC, PPB, NCK, and COC
The primary target audience for this course comprises the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; Oncology pharmacists; Oncology PharmTechs; Oncology clinical officers; physician assistants; and other allied health care professionals.
Statement of Need
General internists, specialist health care professionals, and Primary Care Clinicians must maintain an extensive knowledge base on a wide variety of topics covering all body systems as well as common and uncommon disorders. International Cancer Institute’s Preceptorship Courses aim to leverage the expertise of its Faculty to help clinicians understand best practices in the diagnosis and management of conditions encountered in the clinical setting in sub-Saharan Africa.
At the end of this educational activity, participants should be able to:
- Understand the Epidemiology of Breast cancer in sub-Saharan Africa (SSA)
- Epidemiologic features of breast cancer in Sub-Saharan Africa
- Peculiar features of breast cancer in Sub-Saharan Africa vis-a-vis globally
- Discuss breast cancer screening, risk factors, and protective factors associated with breast cancer
- Discuss the modifiable risk factors for breast cancer
- Be familiar with the indications for screening as well as the best imaging tools
- Understand the principles of chemoprevention, its indications, and side effects
- Understand the indications of referring patients and their relatives for genetic counseling and testing and the implications of BRCA positivity in the management of carriers and patients.
- Recognize the role of pathological diagnosis, staging, molecular subtypes, the prognostic and therapeutic significance of tumor estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expressions for breast cancer
- Be familiar with the diagnostic tools in pathology (fine needle aspiration (FNA) and core biopsy)
- Learn the risk assessment workup of prognostic factors, including staging and biological markers (hormone and HER-2 receptors)
- Familiarize oneself with the implications of the different molecular subtypes of breast cancer in terms of prognosis and selection of appropriate therapies.
- Interpret mammograms and appreciate the role of radiology in breast cancer management
- Familiarize oneself with the indications and limitations of the different imaging modalities available for breast cancer including mammography, ultrasound, magnetic resonance imaging (MRI)
- To identify the best staging modalities.
- To review the optimal treatment strategies for Breast cancer: chemotherapy, hormonal, targeted agents, monoclonal antibodies, etc. Includes Standard of care treatment protocols
- Knowledge regarding the types of systemic therapies (hormonal therapy), chemotherapy and targeted therapy, different regimens, their indications, main side effects, and management for early and advanced disease.
- Discuss fertility preservation.
- Describe the current trends in the locoregional and systemic management of operable early-stage breast
- Understand the different goals of treatment and their implications for early breast cancer.
- Indications, objectives, and limitations of neoadjuvant i.e. preoperative systemic therapy
- Criteria; clinical and biological for decisions about adjuvant chemotherapy, including genomic tests, their indications, and limitations
- To understand the role of the multidisciplinary team in Breast cancer management
- Evaluation of response in the neoadjuvant and advanced setting.
- To be aware of the existence of different therapeutic modalities (surgery, radiotherapy, systemic therapy) as well as specialties e.g., Physical therapy to manage lymphedema.
- Understand the indications and limitations of follow-up procedures for patients with breast cancer.
- To understand the role of Surgery in the management of Breast cancer
- Indications, value, modalities, and limitations of surgery for breast cancer in all stages as well as the different possible sequences
- Understand appropriate surgical procedures at various presentations
- To understand the role of radiotherapy in the management of breast cancer
- Basic principles of radiotherapy in cancer management.
- Indications, value, modalities, and limitations of radiotherapy as well as the different possible sequences.
- To recall the current goals and standard of care in the management of metastatic breast
- Understand the different goals of treatment and their implications for metastatic breast cancer.
- Understand how to evaluate response to treatment in the advanced setting.
- To recognize the existence of breast cancer in male patients
- To understand the characteristics of breast cancer in male patients and main management procedures including special considerations.
- To understand the role of Palliative, supportive, and survivorship care in Breast cancer management
- To recognize the existence of breast cancer in male patients
- To comprehend the most common long-term side effects and other survivorship issues, including psychological that affect patients who had a diagnosis of breast cancer, as well as those living with metastatic disease.
- Understand the complications that derive from disease progression and those that are treatment-associated in the context of being familiar with supportive and palliative care strategies.
- To discuss the role and integration of Biosimilars in breast cancer management
- Introduce the concept of biosimilars, and their comparison with biologics in terms of development, the regulatory pathway of approval, and pharmacovigilance.
- Discuss the role of biosimilars and their impact on access to treatment, cost-utility, and patient outcomes.
- Integrate shared decision-making practices to inform and engage patients on Biosimilars.
- Consider how the availability of Biosimilars will impact clinical practice in SSA.
- Appreciate the research priority areas in breast cancer in SSA
- Explore the disparities in Breast cancer management and the outcomes
- Improving survival in breast cancer patients.
- Opportunities and the role of clinical trials in breast cancer management.
Disclosure of Conflicts of Interest
International Cancer Institute (ICI) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ICI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty must report any financial relationships or contractual relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation and Request for Credit
To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures, and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.
CBP 105: ICI Breast Cancer Preceptorship Course Schedule
Orientation to the course (Prof. Chite Asirwa) Monday, 27th June 2022 3:30-4:00 PM EAT
- Epidemiology of Breast cancer in Sub-Saharan Africa (Dr. Siwillis Mithe) Monday, 27th June 2022 4:00-5:30 PM EAT
- Breast Cancer Screening (Dr. Helena Musau) Wednesday, 29th June 2022 4:00-5:30 PM EAT
- Pathology and its role in Breast Cancer Management (Dr. Shaheen Sayed) Monday 4th July 2022 4:00-5:30 PM EAT
- Imaging in Breast Cancer Management (Prof. Emmanuel Rudakemwa) Wednesday 6th July 2022 4:00-5:30 PM EAT
- Pharmacology of systemic therapies in Breast Cancer (Dr. Irene Weru) Monday, 11th July 2022 4:00-5:30 PM EAT
- Management of Early Breast Cancer (Dr. Yesufe) Wednesday, 13th July 2022 4:00-5:30 PM EAT
- Role of surgery in Breast Cancer Management (Dr. Benjamin Njihia) Monday, 18th July 2022 4:00-5:30 PM EAT
- Role of Radiotherapy in the management of Breast Cancer (Dr. Helena Musau) Wednesday 20th July 2022 4:00-5:30 PM EAT
- Locally Advanced Breast Cancer (Dr. Sitna Mwanzi) Monday 25th July 2022 4:00-5:30 PM EAT
- Metastatic Breast Cancer (Dr. Sitna Mwanzi) Tuesday 26th July 2022 4:00-5:30 PM EAT
- Supportive, Palliative, and Survivorship care in Breast Cancer Care (Dr. Esther Nafula) Wednesday 27th July 2022 4:00-5:30 PM EAT
- Hereditary Breast Cancer & Male Breast Cancer (Dr. Kevin Makori) Monday 1st August 2022 4:00-5:30 PM EAT
- Integration of Biosimilars in Breast Cancer Management in sub-Saharan Africa (SSA) (Dr. David Wata) Tuesday 2nd August 2022 4:00-5:30 PM EAT
- Research priorities & Clinical Trial Opportunities in Breast Cancer in SSA ( Chite Asirwa), Thursday 4th August 20224:00-5:30 PM EAT
Participants should be willing to spend at least 4 hours per week on this online course over a period of 6 weeks. (Duration 24 hours). This program will start when the class is fully subscribed. The course cost is $200.00 for the entire course. There are few sponsorships available on a first-come basis for those who apply. Priority will be given to those working in cancer centers that have formal affiliations/Partnerships with the International Cancer Institute. Apply for sponsorship during the registration of the course
All those interested in registering for this course, please register your information on www.elearning.intercancer.com if you have any questions or queries please send an email to email@example.com or firstname.lastname@example.org
For more information visit our website www.intercancer.com
International Cancer Institute (ICI) ©2022
Your Partner in Cancer Control in SSA
No Reviews found for this course.